Objective To investigate the effect of entecavir combined with pegylated interferon on normalization rate of glutamic-pyruvic transaminase(ALT), clearance rate of hepatitis B E antigen (HBeAg) and conversion rate of hepatitis B E antibody (HBeAb) in patients with chronic hepatitis B(CHB).
Methods A total of 120 patients with CHB were divided into two groups, both groups were treated with basic therapy. The control group was treated with pegylated interferon, and the observation group with entecavir combined with pegylated interferon. The ALT normalization rate, clearance rate of HBeAg, conversion rate of HBeAb and viral breakthrough rate of the two groups were observed and compared. At the same time, the adverse reactions during the treatment were observed.
Results After treatment, the total effective rate of the observation group was significantly higher than that of the control group(P < 0.05); the serum ALT levels of the two groups after 6, 12 and 24 weeks of treatment were significantly improved compared with treatment before(P < 0.05), but the between-group differences were not observed (P>0.05); after 12 and 24 weeks of treatment, the normalization rate of of ALT, clearance rate of HBeAg and conversion rate of HBeAb in the observation group were significantly higher than those in the control group (P < 0.05); after 12 and 24 week of treatment, the viral breakthrough rate in the observation group was significantly lower than that in the control group(P < 0.05); after 24 week of treatment, the levels of Th1/Th2 cytokines in both groups were significantly improved compared with before treatment(P < 0.05); after 24 week of treatment, INF-γ and IL-6 levels in the observation group were significantly better than those in the control group(P < 0.05).
Conclusion Entecavir combined with pegylated interferon in the treatment of CHB patients has better clinical efficacy, which can effectively inhibit HBV replication, and has higher safety and synergistic antiviral effect.
DownLoad: